EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy PFE?
Source: moomoo
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.310
Low
24.00
Averages
28.56
High
35.00
Current: 27.310
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Unveils New Therapy Data at ASCO Meeting
- New Therapy Evidence: Pfizer presented new evidence for LORBRENA® and BRAFTOVI® at the ASCO meeting, reinforcing their status as standard treatments for ALK-positive non-small cell lung cancer and BRAF-mutant colorectal cancer, which is expected to significantly improve patient survival rates and quality of life.
- Early Treatment Potential: The clinical trial of TALZENNA® plus XTANDI® in metastatic castration-sensitive prostate cancer showed significant improvements in radiographic progression-free survival (rPFS), indicating that early intervention may yield better treatment outcomes and enhancing Pfizer's competitive position in the prostate cancer market.
- Pipeline Advancement: Updates on novel mechanisms such as PF-08634404 and sigvotatug vedotin across various solid tumors demonstrate their potential applications in different cancer types, potentially providing more treatment options for the future and further solidifying Pfizer's leadership in oncology.
- Clinical Research Findings: Pfizer will share data from over 40 research abstracts at ASCO, including three late-breaking presentations and eight oral presentations, emphasizing its ongoing innovation in cancer treatment and commitment to patients, which is expected to drive future growth and market share enhancement.
See More
AbbVie vs. Pfizer: A Financial Comparison
- Patent Management Advantage: AbbVie has effectively managed its patent portfolio with 130 patents surrounding its immunology therapy Humira, which was the world's best-selling drug for six consecutive years, while Pfizer's Comirnaty took the lead during the pandemic, AbbVie's drug lineup shows greater market resilience.
- Sales Growth Potential: AbbVie's Skyrizi and Rinvoq are projected to generate $17.6 billion and $8.3 billion in sales in 2025, respectively, totaling $25.9 billion, which significantly surpasses Humira's $21.2 billion in 2022, highlighting the diversification and profitability of its product portfolio.
- Dividend Safety: While Pfizer boasts a dividend yield of 6.3%, its payout ratio of 107% indicates unsustainability, whereas AbbVie offers a 3.2% yield with a more manageable payout ratio of 65%, suggesting a more stable dividend payment structure.
- Financial Growth Outlook: AbbVie expects to achieve revenue of around $67 billion in 2026, reflecting a 9.5% increase, while Pfizer's revenue is projected to decline by 2.5%, showcasing AbbVie's clear advantage in financial growth prospects.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
Pfizer's Xianweiying Weight Management Treatment Available for Pre-Order in China
- Increased Market Competition: Pfizer's GLP-1 weight management treatment Xianweiying is now available for pre-order in China, intensifying competition with rivals like Novo Nordisk and Eli Lilly in a market analysts project to be worth billions of dollars.
- Pricing and Shipping: A 1.2 ml Xianweiying injector pen is priced at 489 yuan ($72) according to JD.com, with shipping set to begin on April 27, a pricing strategy that could influence consumer choices and reshape market dynamics.
- Sales Data Comparison: Jefferies reports that Novo's Wegovy generated sales of 260 million yuan ($38 million) in 2025, while Innovent's Xinermei achieved 416 million yuan ($61 million), highlighting the substantial market potential for weight-loss drugs.
- Strategic Acquisitions and Licensing: Pfizer licensed the commercialization rights for Xianweiying in mainland China in February and has acquired obesity drug developer Metsera, further solidifying its position in the rapidly growing weight-loss drug market.
See More
Pfizer Executive Andrew Baum to Depart Company
- Executive Departure: Pfizer's Chief Strategy and Innovation Officer Andrew Baum is set to leave the company by the end of 2026 after joining in 2024 to reform the company's strategic direction, indicating ongoing efforts in operational simplification.
- New Role: Baum will transition to a senior strategic advisor role under CEO Albert Bourla, suggesting that while he departs, his influence may still shape future strategic decisions at Pfizer.
- Background Experience: Prior to Pfizer, Baum led global healthcare at Citi and served as managing director at Morgan Stanley for over 15 years, bringing extensive industry experience that supports Pfizer's strategic adjustments.
- Company Response: Pfizer confirmed its commitment to regularly evaluate operations to ensure optimal positioning for both short-term and long-term goals, with management changes aimed at accelerating decision-making and fostering innovation across the enterprise.
See More
Pfizer Accelerates Catch-Up in Weight Loss Drug Market
- Increased Market Competition: Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2b trials, and while its efficacy is similar to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, its monthly injection regimen could make it a more appealing option, thereby putting pressure on the existing market.
- Sales Fluctuations: Novo Nordisk's Wegovy saw an increase in total prescriptions for 2025, yet it declined before year-end, with expectations of a 5% to 13% drop in revenue due to weakness in its weight-loss drug business, highlighting the market's sensitivity to pricing.
- Significant Growth for Eli Lilly: Eli Lilly's Zepbound achieved a remarkable 175% revenue growth last year, rising from $4.9 billion to $13.5 billion, although its growth rate began to slow in Q4, reflecting the impact of intensified market competition.
- Uncertain Future Outlook: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944; while still in early stages, successful trials could reshape the GLP-1 drug market landscape, increasing pressure on Novo Nordisk and Eli Lilly.
See More
Pfizer Unveils New Therapy Data at ASCO Meeting
- New Therapy Evidence: Pfizer presented new evidence for LORBRENA® and BRAFTOVI® at the ASCO meeting, reinforcing their status as standard treatments for ALK-positive non-small cell lung cancer and BRAF-mutant colorectal cancer, which is expected to significantly improve patient survival rates and quality of life.
- Early Treatment Potential: The clinical trial of TALZENNA® plus XTANDI® in metastatic castration-sensitive prostate cancer showed significant improvements in radiographic progression-free survival (rPFS), indicating that early intervention may yield better treatment outcomes and enhancing Pfizer's competitive position in the prostate cancer market.
- Pipeline Advancement: Updates on novel mechanisms such as PF-08634404 and sigvotatug vedotin across various solid tumors demonstrate their potential applications in different cancer types, potentially providing more treatment options for the future and further solidifying Pfizer's leadership in oncology.
- Clinical Research Findings: Pfizer will share data from over 40 research abstracts at ASCO, including three late-breaking presentations and eight oral presentations, emphasizing its ongoing innovation in cancer treatment and commitment to patients, which is expected to drive future growth and market share enhancement.
See More
AbbVie vs. Pfizer: A Financial Comparison
- Patent Management Advantage: AbbVie has effectively managed its patent portfolio with 130 patents surrounding its immunology therapy Humira, which was the world's best-selling drug for six consecutive years, while Pfizer's Comirnaty took the lead during the pandemic, AbbVie's drug lineup shows greater market resilience.
- Sales Growth Potential: AbbVie's Skyrizi and Rinvoq are projected to generate $17.6 billion and $8.3 billion in sales in 2025, respectively, totaling $25.9 billion, which significantly surpasses Humira's $21.2 billion in 2022, highlighting the diversification and profitability of its product portfolio.
- Dividend Safety: While Pfizer boasts a dividend yield of 6.3%, its payout ratio of 107% indicates unsustainability, whereas AbbVie offers a 3.2% yield with a more manageable payout ratio of 65%, suggesting a more stable dividend payment structure.
- Financial Growth Outlook: AbbVie expects to achieve revenue of around $67 billion in 2026, reflecting a 9.5% increase, while Pfizer's revenue is projected to decline by 2.5%, showcasing AbbVie's clear advantage in financial growth prospects.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
Pfizer's Xianweiying Weight Management Treatment Available for Pre-Order in China
- Increased Market Competition: Pfizer's GLP-1 weight management treatment Xianweiying is now available for pre-order in China, intensifying competition with rivals like Novo Nordisk and Eli Lilly in a market analysts project to be worth billions of dollars.
- Pricing and Shipping: A 1.2 ml Xianweiying injector pen is priced at 489 yuan ($72) according to JD.com, with shipping set to begin on April 27, a pricing strategy that could influence consumer choices and reshape market dynamics.
- Sales Data Comparison: Jefferies reports that Novo's Wegovy generated sales of 260 million yuan ($38 million) in 2025, while Innovent's Xinermei achieved 416 million yuan ($61 million), highlighting the substantial market potential for weight-loss drugs.
- Strategic Acquisitions and Licensing: Pfizer licensed the commercialization rights for Xianweiying in mainland China in February and has acquired obesity drug developer Metsera, further solidifying its position in the rapidly growing weight-loss drug market.
See More
Pfizer Executive Andrew Baum to Depart Company
- Executive Departure: Pfizer's Chief Strategy and Innovation Officer Andrew Baum is set to leave the company by the end of 2026 after joining in 2024 to reform the company's strategic direction, indicating ongoing efforts in operational simplification.
- New Role: Baum will transition to a senior strategic advisor role under CEO Albert Bourla, suggesting that while he departs, his influence may still shape future strategic decisions at Pfizer.
- Background Experience: Prior to Pfizer, Baum led global healthcare at Citi and served as managing director at Morgan Stanley for over 15 years, bringing extensive industry experience that supports Pfizer's strategic adjustments.
- Company Response: Pfizer confirmed its commitment to regularly evaluate operations to ensure optimal positioning for both short-term and long-term goals, with management changes aimed at accelerating decision-making and fostering innovation across the enterprise.
See More
Pfizer Accelerates Catch-Up in Weight Loss Drug Market
- Increased Market Competition: Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2b trials, and while its efficacy is similar to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, its monthly injection regimen could make it a more appealing option, thereby putting pressure on the existing market.
- Sales Fluctuations: Novo Nordisk's Wegovy saw an increase in total prescriptions for 2025, yet it declined before year-end, with expectations of a 5% to 13% drop in revenue due to weakness in its weight-loss drug business, highlighting the market's sensitivity to pricing.
- Significant Growth for Eli Lilly: Eli Lilly's Zepbound achieved a remarkable 175% revenue growth last year, rising from $4.9 billion to $13.5 billion, although its growth rate began to slow in Q4, reflecting the impact of intensified market competition.
- Uncertain Future Outlook: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944; while still in early stages, successful trials could reshape the GLP-1 drug market landscape, increasing pressure on Novo Nordisk and Eli Lilly.
See More
